Phases of cml
Reading File
Finding Sources
Searching PubMed
"chronic myeloid leukemia" AND phases
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
I now have comprehensive information from Goldman-Cecil, Harrison's 22E (2025), and Washington Manual. Here is the full answer:
Phases of CML (Chronic Myeloid Leukemia)
CML is a triphasic disease driven by the BCR-ABL fusion gene (Philadelphia chromosome). All cases start as a hematopoietic stem cell disorder that, if untreated, progresses through three phases.
1. Chronic Phase (CP)
- Most common presentation: >90% of patients are diagnosed here, often incidentally on a routine CBC
- Blasts: <10% in peripheral blood and bone marrow (WHO) / <15% (ELN)
- Features:
- Massive leukocytosis with the entire spectrum of myeloid differentiation (myeloblasts to mature neutrophils)
- Basophilia and eosinophilia
- Thrombocytosis common; anemia may be present
- Splenomegaly (left-sided abdominal pain, early satiety)
- Often asymptomatic early on
- Natural history: Untreated CP will progress to advanced phase within a mean of 3-5 years
- Prognosis with TKI therapy: Excellent - estimated 8-10 year survival rates are very high in well-treated populations
2. Accelerated Phase (AP)
| Criterion | WHO (2022) | ELN |
|---|---|---|
| Blasts | 10-19% PB or BM | 15-29% PB or BM |
| Basophils | ≥20% | ≥20% |
| Clonal evolution | Additional cytogenetic abnormalities (beyond Ph) | Same |
| Thrombocytopenia | <100 × 10⁹/L unrelated to therapy | Same |
| Blasts + promyelocytes | - | ≥30% PB |
Note: The latest WHO classification (5th ed.) has proposed eliminating AP as a separate entity and reclassifying these patients as "high-risk CML." However, Harrison's (22E, 2025) argues the AP definition should be maintained because such patients have significantly worse survival than high-risk CP and should be treated differently.
- Symptoms: Increasing constitutional symptoms - fever, bone pain, night sweats, weight loss
- Historical median survival: <2 years (improving to ~50% 3-year survival with TKI therapy)
- Common new cytogenetic changes at progression: +Ph (double Ph), trisomy 8, isochromosome 17q, trisomy 19
- Treatment: TKIs (dasatinib, bosutinib preferred; nilotinib not used), consider allogeneic HSCT
3. Blast Phase / Blast Crisis (BP)
| Criterion | WHO | ELN / Harrison's |
|---|---|---|
| Blasts | ≥20% PB or BM | ≥30% PB or BM |
| Extramedullary blasts | Sheets of blasts in skin, soft tissue, bone | Same |
- Behaves like acute leukemia (AML or ALL)
- Myeloid BP: ~60% of cases (anti-AML chemotherapy + TKI)
- Lymphoid BP: ~25% of cases (TdT-positive, peroxidase-negative blasts); treated like Ph+ ALL
- Rare subtypes: Erythroid, promyelocytic, monocytic, megakaryocytic
- Prognosis: Very poor - historical survival <1 year; with TKI + chemotherapy, complete remission rates of 30-50% and median survival ~12 months
- Treatment: TKI + chemotherapy + allogeneic stem cell transplantation
Key Classification Differences: WHO vs. ELN
| Feature | WHO | ELN |
|---|---|---|
| Accelerated phase blasts | 10-19% | 15-29% |
| Blast phase blasts | ≥20% | ≥30% |
The WHO criteria are more sensitive (lower blast threshold). The ELN criteria are more commonly used in clinical practice and trials. - Goldman-Cecil Medicine, p. 1938
Progression Summary
Chronic Phase → Accelerated Phase → Blast Crisis
(<10% blasts) (10-19% blasts) (≥20-30% blasts)
~85-90% ~5-10% ~5-10%
of presentations de novo; rest de novo; rest evolve
evolve from CP from CP/AP
The bulk of genetic changes driving progression occur at the chronic-to-accelerated phase transition; relatively minor additional changes then occur from AP to blast phase. - Harrison's Principles of Internal Medicine, 22E (2025), p. 881
Recent update (PMID: 40094679): The 2025 JAMA review by Jabbour & Kantarjian confirms TKI therapy has dramatically improved survival across all phases, with treatment-free remission (TFR) now achievable in ~40-60% of patients who reach deep molecular response.
Why there is thrombocytopenia and anemia in cml
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Excellent - I now have all the source material needed. Here is a complete, well-sourced answer:
Why Anemia and Thrombocytopenia Occur in CML
First - an important nuance
In early/chronic phase CML, anemia is mild and thrombocytopenia is not typical - in fact, thrombocytosis (high platelet count) is a classic finding. This is because BCR-ABL does not inhibit differentiation; it drives proliferation of granulocytic and megakaryocytic progenitors, leading to excess platelets. - Robbins Basic Pathology, p. 406
Thrombocytopenia (and worsening anemia) are markers of disease progression into accelerated/blast phase.
Causes of Anemia in CML
1. Marrow Replacement / Myelophthisis
The dominant mechanism. The BCR-ABL-driven clone massively expands granulocytic and megakaryocytic precursors, filling the marrow. This creates a high myeloid-to-erythroid ratio (>4:1) - erythroid progenitors are physically crowded out and suppressed, reducing red cell production (hypoproliferative anemia). - Creasy & Resnik's MFM, p. 1194; Goldman-Cecil Medicine, p. 1941
2. Splenic Sequestration and Hypersplenism
CML causes massive splenomegaly due to extramedullary hematopoiesis. The enlarged spleen:
- Sequesters red blood cells in splenic cords
- Splenic macrophages increase phagocytosis of RBCs
- This creates a hypersplenic state with shortened RBC survival and dilutional anemia - Robbins & Cotran Pathologic Basis of Disease, p. 589
3. Ineffective / Increased Cell Turnover
Hypermetabolism from rapidly turning over leukemic cells consumes nutrients and suppresses normal erythropoiesis.
4. Advanced Phase: Failure of Residual Hematopoiesis
In blast phase, the residual normal bone marrow progenitors are nearly completely replaced. Severe anemia at this stage reflects near-total marrow failure for erythroid lineage, similar to acute leukemia. Bleeding from thrombocytopenia compounds the anemia.
Causes of Thrombocytopenia in CML
1. Splenic Sequestration (most important for chronic-phase thrombocytopenia)
The normal spleen holds ~30-40% of the platelet mass. With massive splenomegaly in CML:
"With splenomegaly, up to 80-90% of the total platelet mass may be sequestered in the interstices of the red pulp, producing thrombocytopenia." - Robbins & Cotran, p. 589
This is the main reason for thrombocytopenia even when the marrow is still producing platelets.
2. Marrow Failure in Advanced Disease
As CML progresses to accelerated and blast phase, the leukemic blasts crowd out megakaryocytes:
"After a variable period, ~50% of patients enter an accelerated phase marked by increasing anemia and new thrombocytopenia, and the appearance of additional cytogenetic abnormalities." - Robbins & Cotran, p. 583
This represents a reversal from the early-phase thrombocytosis: megakaryocytes, which were initially over-driven by BCR-ABL, are now being displaced by the undifferentiated blast population.
3. Clonal Evolution with Megakaryocyte Dysplasia
New cytogenetic abnormalities acquired in progression (trisomy 8, isochromosome 17q, +Ph) disrupt megakaryocyte differentiation, producing fewer and dysfunctional platelets.
4. TKI-related (Iatrogenic)
Thrombocytopenia is also a well-known side effect of TKI therapy (imatinib, dasatinib, bosutinib, etc.) - the drugs suppress BCR-ABL-driven megakaryopoiesis, which can undershoot normal platelet production. This is treatment-related, not disease-related.
Summary Table
| Mechanism | Anemia | Thrombocytopenia | Phase |
|---|---|---|---|
| Marrow replacement (myeloid crowding) | ✓ (high M:E ratio) | ✓ (late, blasts displace megakaryocytes) | All, worsens with progression |
| Splenic sequestration / hypersplenism | ✓ (RBC trapping) | ✓ (up to 80-90% platelets trapped) | Chronic and beyond |
| Blast-phase marrow failure | ✓ (severe) | ✓ (severe) | Blast crisis |
| Clonal evolution/cytogenetic changes | - | ✓ (megakaryocyte dysplasia) | Accelerated/blast |
| TKI therapy (iatrogenic) | ✓ (mild) | ✓ (myelosuppression) | Any (on treatment) |
Key point: In chronic phase, mild anemia is expected but thrombocytopenia is usually absent (platelets are typically normal or high). Thrombocytopenia <100 × 10⁹/L unrelated to therapy is actually one of the diagnostic criteria for accelerated phase - it signals that the disease is losing its capacity to sustain megakaryopoiesis. - Harrison's Principles of Internal Medicine, 22E (2025), p. 881
This is a shared conversation. Sign in to Orris to start your own chat.